Targeted Disease(s):
Pulmonary Fibrosis

Purpose of Study:

The HARBOR Study is evaluating the safety and effectiveness of a potential medicine (HZN-825) that may slow disease progression in participants with idiopathic pulmonary fibrosis (IPF).

Study Dates:
August 25, 2021 - September 30, 2023

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Lead Institution:
Horizon Therapeutics

Funding Source:
Horizon Therapeutics

ClinicalTrails.gov Identifier:
NCT05032066

Register for Trial
Asthma Educator Institute
, | Jul 11, 2022
Freedom From Smoking Virtual Clinic
San Jose, CA | Oct 24, 2022